Printer Friendly

Vectura announces positive Phase II data for VR496 in cystic fibrosis.

M2 PHARMA-March 25, 2011-Vectura announces positive Phase II data for VR496 in cystic fibrosis(C)2011 M2 COMMUNICATIONS

25 March 2011 - UK-based Vectura Group plc (LON: VEC) today announced positive data from a Phase II clinical study for its orally inhaled product, VR496, a potentially multi-modal treatment for respiratory symptoms associated with airway disorders such as cystic fibrosis (CF).

Seventy-seven CF patients with a median age of 23 years were randomised, double-blind, to placebo or one of three active dose groups. Study treatment was administered twice-daily at home for a period of four weeks. Subjects with established lung inflammation and impaired sputum clearance were eligible for enrolment. Patients with a history of significant haemoptysis (coughing up blood) or unstable disease were excluded.

VR496 was found to be safe and well tolerated with over 90% of patients successfully completing the study. Dosing compliance was high, with 91% of prescribed study treatment administered. Anti-inflammatory activity was demonstrated via reductions, from Baseline to Week 4, in induced sputum neutrophil elastase and total cell counts when compared to placebo. Active treatment also resulted in clearer and thinner sputum that was easier to clear from the airways compared with placebo.

VR496 is Vectura's proprietary formulation of dry powder heparin sodium and has been designated orphan drug status by the European Medicines Agency (EMA) and Food and Drug Administration (FDA).

Chris Blackwell, chief executive of Vectura, said that this study confirms the potential therapeutic benefit of VR496 in a variety of airway disorders and justifies further clinical evaluation.

((Comments on this story may be sent to

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Article Type:Clinical report
Date:Mar 25, 2011
Previous Article:Lexicon Pharmaceuticals adds Pablo Lapuerta chief medical officer.
Next Article:HeartWare gets nod form Therapeutic Goods Administration in Australia.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters